Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.

Future oncology (London, England)·2025

Same author

Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032.

medRxiv : the preprint server for health sciences·2025

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Emerging therapeutic targets for soft tissue sarcoma.

Jason L Smith¹, Richard F Riedel

¹Divisions of Hematology, Medical Oncology, Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA. smith426@mc.duke.edu

Current Oncology Reports

|April 28, 2011

Summary

Soft tissue sarcomas (STS) are rare adult cancers. This review explores new treatments and targets to improve systemic therapy for these heterogeneous mesenchymal malignancies.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Experiment Videos

Last Updated: Jun 2, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Area of Science:

Oncology
Cancer Research
Malignant Neoplasms

Background:

Soft tissue sarcomas (STS) are rare adult cancers originating from mesenchymal tissues, accounting for about 1% of adult malignancies.
The rarity and heterogeneity of STS present significant challenges for systematic treatment research.
Histological subtyping of STS is established, but therapeutic strategies are only recently beginning to incorporate these distinctions.

Purpose of the Study:

To review and highlight emerging therapeutic targets for soft tissue sarcomas.
To discuss novel therapies with the potential to advance current systemic treatment options for STS.
To provide an updated perspective on the evolving landscape of STS treatment.

Main Methods:

Literature review of recent advancements in soft tissue sarcoma research.
Analysis of emerging therapeutic targets and novel treatment modalities.
Synthesis of current knowledge on differentiated STS therapy approaches.

Main Results:

Identification of several promising molecular targets within STS subtypes.
Overview of novel systemic therapies, including targeted agents and immunotherapies.
Discussion of the increasing importance of personalized medicine in STS treatment.

Conclusions:

Emerging targets and therapies show significant potential to enhance systemic treatment for soft tissue sarcomas.
A more tailored, subtype-specific approach to STS therapy is becoming increasingly feasible.
Continued research into novel therapeutic strategies is crucial for improving outcomes in STS patients.